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ABSTRACT
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine playing crucial role in immun-
ity. MIF exerts a unique tautomerase enzymatic activity that has relevance concerning its multiple func-
tions and its small molecule inhibitors have been proven to block its pro-inflammatory effects. Here we
demonstrate that some of the E-2-arylmethylene-1-tetralones and their heteroanalogues efficiently bind to
MIF’s active site and inhibit MIF tautomeric (enolase, ketolase activity) functions. A small set of the syn-
thesised derivatives, namely compounds (4), (23), (24), (26) and (32), reduced inflammatory macrophage
activation. Two of the selected compounds (24) and (26), however, markedly inhibited ROS and nitrite
production, NF-jB activation, TNF-a, IL-6 and CCL-2 cytokine expression. Pre-treatment of mice with com-
pound (24) exaggerated the hypothermic response to high dose of bacterial endotoxin. Our experiments
suggest that tetralones and their derivatives inhibit MIF’s tautomeric functions and regulate macrophage
activation and thermal changes in severe forms of systemic inflammation.
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Macrophage migration inhibitory factor (MIF) was the first repre-
sentative of those polypeptide immune mediators that have been
grouped later as “cytokines”1,2. Since its description 50 years ago
MIF has accumulated a bewildering variety of immune and non-
immune functions3. MIF has been also considered to be a missing
link between inflammation and tumorigenesis4.
MIF structure shares no homology with other known cytokines.
Its structural relatives are the mammalian enzyme, D-dopachrome-
tautomerase (DDT)5, and the prokaryotic enzymes: chorismate
mutase, 5-carboxymethyl-2-hydroxymuconate-isomerase (CHMI),
trans- and cis-3-chloroacrylic acid dehalogenase (CaaD and cis-
CaaD, respectively), and 4-oxalocrotonate-tautomerase (4-OT)6,7.
MIF exists in a homotrimeric form of 12.4 kD monomers. In each
monomer, two a-helices are packed against a four-stranded
b-sheet8. There are reports, however, of the occurrence of a
dimeric form of MIF9 as well as of other oligomerisation states10
and also of heteromers11.
More than twenty years ago Rorsman et al. reported that recom-
binant MIF catalyses the tautomerisation of the non-naturally occur-
ring D-dopachrome, transforming the coloured compound to the
colourless dihydroindole carboxylic acid (DHICA)12, however, L-dopa-
chrome methyl ester (a melanin precursor) have also been found a
suitable substrate. This was soon followed by the identification of
phenylpyruvate and p-hydroxyphenylpyruvate as alternate substrates
for the tautomeric activity of MIF13. In the homotrimeric MIF, the
catalytic site is located between each of two adjacent monomers.
Acidic pKa of the N-terminal proline of each MIF monomer is
thought to play a crucial role in the keto-enol tautomerisation reac-
tion7. A direct link between cytokine activity and tautomerase cata-
lytic site of MIF has been reported14, although a “true” endogenous
small molecule ligand has yet to be found. Blocking of endogenous
MIF by a small molecule such as “ISO-1” and neutralisation of MIF by
anti-MIF antibodies or by plant-derived MIF inhibitors reduces the
manifestations of inflammatory conditions such as type II collagen-
induced arthritis, immunologically induced kidney disease, experi-
mental autoimmune encephalomyelitis, experimental allergic neuritis,
immunoinflammatory diabetes, experimental autoimmune myocardi-
tis, irradiation-induced acute pneumonitis, sepsis, and ischemia–re-
perfusion injury15–18. Therefore, inhibitors of MIF tautomerase hold
promise for prospective clinical use in many pathologic conditions19.
Development of individualised therapy targeting MIF in these condi-
tions is expected based on the human genetic data supporting the
role of high-expression MIF alleles in the clinical severity and end-
organ complications of a number of inflammatory disorders20.
Molecular modelling techniques have been used lately to find
“designer” inhibitors of promising potential21–23. The reported MIF
enzyme inhibitors include long-chain fatty acids, E-2-fluoro-p-
hydroxycinnamate, dopachrome analogues, tryptophan and tyro-
sine derivatives24, or coumarin- and chromenone derivatives19,25.
A large variety of natural compounds show inhibitory effect of
the MIF enzyme including e.g. ellagic acid26. According to previ-
ous results, caffeic acid proved to be an efficient inhibitor of MIF
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tautomerase when using either dopachrome27 or phenylpyru-
vate28 as the substrate. Phenylpyruvate tautomerase was
also inhibited by curcumin28, a substance known long for its anti--
inflammatory and cancer chemopreventive properties – a constitu-
ent of the spice turmeric29. Therefore, the selection of our
potential MIF inhibitors was based on the unsaturated ketone –
structural motif – found in several natural or synthetic MIF inhibi-
tors such as coumarines and chromenones and cinnamates such
as caffeic acid, curcumin, and N-acetyl-p-benzoquinone19. In add-
ition, according to our previous studies, some tetralone derivatives
proved to be efficient MIF inhibitors30.
Based on these findings, we have focused on the group of cyc-
lic a,b-unsaturated ketones to study their inhibitory effects
towards the MIF tautomerase activity. To find compounds with
good inhibitory effect, we have previously selected some different
model compounds as 2-arylidenecycloalkanones, 2,5-diarylidene-
cyclopentanone and few 2-arylidene-1-tetralones30. The enol-keto
tautomeric conversion of phenylpyruvate (ketonase reaction) was
investigated by spectrophotometric method. From the substances
investigated, several proved to be good inhibitors of the tauto-
merase activity of the MIF enzyme.
This paper deals with a large molecular library of E-2-aryl-
methylene-1-tetralones and their hetero-analogues related to nat-
urally occurring flavonoids. Some representatives of this latter
group have previously been proven as potent MIFtautomerase
inhibitors28,31. At this end, potential analogies between the bio-
logical roles of flavonoids and melanins (or precursors thereof)
deserve particular attention32 concerning possible implication of
MIF in (neuro-) melanogenesis33.
The molecule library we have used here shows large structural
diversity. We have chosen cyclic ketones of different size and with
different heteroatoms as skeletal compounds, and applied various
aryl side chains to find an optimal lead compound. We have var-
ied the size of the ketone ring, the aromatic substituent C-ring
(with electron withdrawing and electron donating groups), and
also changed the type of the B-ring (see Figure 1 and Table 1).
Through in silico methods, we aimed to identify the key interac-
tions required for MIF inhibitory activity. In addition, we tested
the biological activity of the best tautomerase inhibitors from the
molecular library in lipopolysaccharide-(LPS)-induced macrophages
and also in LPS-treated mice.
Material and methods
Reagents
All reagents were purchased from Sigma-Aldrich (St. Louis, MO)
unless otherwise indicated. A molecular library of 38 structurally
related known compounds has been studied. Based on their struc-
tural features, this library could be further divided into two sub-
groups (Table 1). The group I consists of a 1-indanone derivative
(1), substituted arylmethylene–tetralones (2, 4–18), heteroaryl–me-
thylene–tetralones (19–26) and a benzosuberone derivative (3).
Group II contains chromanones and their thioanalogues (27–38). All
of the compounds investigated here have been prepared by base
catalysed aldol condensation, the conditions (temperature, solvent
and catalyst) of the synthetic method were a little bit different. See
the detailed methods below. (Their structure is depicted in
Supplementary material’s Figure S1 and in Table 1; the synthesis
method is in Ref. [34].) Scheme 1 describes the general synthetic
method. The preparation of the E-2-phenylmethylene-1-indanone
(1), E-2-phenylmethylene-1-benzosuberone (3) and E-2-arylmethy-
lene-1-tetralones (2, 4–26) was carried out at room temperature in
ethanol. The synthesis of the E-3-arylmethylenechroman-4-ones and
E-3-arylmethylene-1-thiochroman-4-ones (27–36) was performed at
140 C with piperidine as a catalyst without solvent. The 4-thiochro-
manone-1-oxide (36) and 1,1-dioxide (37) was obtained according
to literature methods35. All of the compounds were purified by
recrystallisation from methanol and with column chromatography.
Their structural characterisation is based on FT-IR methods and pre-
viously published NMR data36–53. Thus, all of the test compounds
studied here have been published elsewhere and characterised, see
the references above. All of the compounds were proved as E-iso-
mer based on the NMR measurements54.
Tautomerase assay
The enol-keto tautomeric conversion of phenylpyruvate (ketonase
reaction) was assessed at room temperature by monitoring the
decrease in absorbance at 288nm on a dual path Shimadzu 2100
UV spectrophotometer (Shimadzu, Kyoto, Japan) according to
Taylor et al.55 with minor modifications. Briefly, the 0.72ml reaction
mixture consisted of the enzyme at a final concentration of 0.4mg/
ml and the substrate in a 50mM sodium phosphate buffer (pH ¼
6.5). The phenylpyruvate substrate was dissolved fresh in absolute
ethanol to yield a final concentration of 100mM. The reaction was
monitored for 75 s at room temperature. A recombinant human
MIF (from ATGen Co. Ltd., Seoul, Republic of Korea) was used as
the enzyme source. Inhibitors were dissolved fresh in ethanol or
DMSO. Ethanol or DMSO did not affect the enzyme reaction at the
amounts applied. The compounds were diluted to achieve final
concentrations of 200, 100, 50, 20, 5, 1, and 0.5mM in the reaction
mixture. All data presented have been derived from consonant
measurements repeated at least three times. As reference inhibitor
caffeic acid (ketonase and enolase IC50: 0.5 and 2.0mM respectively)
was used28. The areas under the curves obtained with and without
the inhibitors were used to compare the conversion rates of the
substrate. The IC50 value – the concentration of the given com-
pound required to achieve 50% inhibition56 –was obtained by a
nonlinear curve fitting (Sigma Plot 2000, SPSS Inc., Chicago, IL, USA)
on the data obtained with the different concentrations of the
inhibitor using the equation: f¼minþ(maxmin)/(1þ(x/EC50)nHill).
Molecular modelling
Molecular modelling was applied as a means of gathering informa-
tion on the structure’s binding mode. Glide docking was conducted
on various MIF-ligand crystallographic structures in Extra Precision
mode without constraints. Dockings with core restrictions using
two types of docking output structures were examined to assess
the favoured binding mode. Covalent docking was used to visualise
the hypothesised adduct formation with Pro1. Molecular Dynamics
simulations were used to assess the stability of the reversible com-
plexes and explore the nature of the binding site interactions.
The crystallographic structure of MIF in complex with an inhibitor
was obtained from Protein Data Bank (PDB 6B1K). All calculations
were carried out with the modules of Schr€odinger Suites 2019–2
(Schr€odinger, LLC, New York, NY) in Maestro. The protein was pre-
pared by adding hydrogens and missing side chains. Water
Figure 1. General formula of the test compounds (1–38).
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molecules, sulphate ions and glycerol molecules were removed, as
well as ligands in the active sites formed by chains A–B and B–C.
Hydrogen bonds were optimised at pH ¼ 7.4, followed by Impref
minimisation using OPLS3e force field. The 3D structures of the
ligands were determined by LigPrep at pH ¼ 7.4 using OPLS3e force
field. The grid box for docking was centred on the original ligand
between chains A and C with automatic ligand size. Initial Glide
docking experiments were run without any pharmacological con-
straints. Type I constrained docking was run with a tolerance of
0.1Å, while in Type II constrained docking, the tolerance was set to
2Å. Docking scores and MM/GBSA calculation results of reversible
complexes in kcal/mol are summarised in Table 2. The model was
validated by docking 3-(3,4-dihydroxyphenyl)-7-hydroxy-4H-chromen-
4-one (RCSB ligand ID 47X, co-crystallized in MIF PDB entry 3L5R)
with extra precision and without using constraints. Four viable poses
were found, all of them similar to the binding mode observed in
3L5R, with docking scores ranging between 9.975 and
10.533 kcal/mol. Ligand RMSD values ranging from 0.7428 to
1.6388Å for all heavy atoms were calculated, while values between
0.3643 and 0.7292Å were calculated for the 7-hydroxy-4H-chromen-
4-one core residing in the solvent inaccessible binding pocket of
MIF. RMSD values for the ligand were calculated after binding site
alignment considering residues within 5Å range of the ligand, and
3L5R was used as the reference structure in its native form.
Covalent dockings were run in CovDock within Maestro. The
following custom covalent mechanism protocol was created for
this purpose:





Pro1A is present in the conjugate acid form, and was manually
deprotonated before initiating covalent dockings. The same core






1 – Phenyl 82.8 ± 16.5 20.2 ± 3.9
2 CH2 Phenyl 127 ± 20 113 ± 16
3 (CH2)2 Phenyl 84.0 ± 15.3 129 ± 19
4 CH2 40- CH3-phenyl 16.5 ± 3.4 2290 ± 343
5 CH2 40-OCH3-phenyl 57.0 ± 14.1 33.4 ± 8.8
6 CH2 40-Cl-phenyl 59.1 ± 9.7 42.8 ± 3.1
7 CH2 20-Cl-phenyl 2640 ± 406 458 ± 73
8 CH2 40-Br-phenyl 52.2 ± 11.5 232 ± 54
9 CH2 30-Br-phenyl 7340 ± 1024 3350 ± 424
10 CH2 40-F-phenyl 72.4 ± 3.4 42.1 ± 4.3
11 CH2 20,60-(Cl)2-phenyl 58.9 ± 10.3 35.5 ± 5.9
12 CH2 30,40-(Cl)2-phenyl 2620 ± 696 91.5 ± 9.0
13 CH2 20,40-(Cl)2-phenyl 16.9 ± 4.2 301 ± 42
14 CH2 40-COOH-phenyl 187 ± 32 37.7 ± 16.3
15 CH2 40-(NCH3)2--phenyl 90.2 ± 15.1 495 ± 101
16 CH2 40-CN-phenyl 146 ± 17 43.2 ± 12.4
17 CH2 30,40-(OCH3)2 -phenyl 585 ± 94 302 ± 63
18 CH2 30,40-(OCH2O)-phenyl 50.7 ± 6.0 213 ± 31
19 CH2 20-Furyl 57.7 ± 12.6 25.4 ± 4.7
20 CH2 20-Thienyl 54.0 ± 5.5 52.3 ± 7.6
21 CH2 20-Pyrrolyl 142 ± 31 125 ± 39
22 CH2 N-Methyl-20-pyrrolyl 23.8 ± 3.8 27.8 ± 5.6
23 CH2 30-Indolyl 58.8 ± 10.6 2.89 ± 0.75
24 CH2 20-Pyridyl 5.63 ± 0.94 28.6 ± 7.4
25 CH2 30-Pyridyl 20.3 ± 5.5 28.6 ± 6.0
26 CH2 40-Pyridyl 21.0 ± 6.9 209 ± 77
27 O Phenyl 267 ± 59 1740 ± 483
28 O 40- CH3-phenyl 102 ± 19 3620 ± 829
29 O 30- CH3-phenyl 56.1 ± 8.8 443 ± 112
30 O 40-OCH3-phenyl 96.0 ± 29.9 425 ± 70
31 O 30-OCH3-phenyl 97.0 ± 20.7 205 ± 32
32 O 20-OCH3-phenyl 4.31 ± 1.34 1260 ± 159
33 O 40-Br-phenyl 311 ± 77 1890 ± 438




419 ± 113 –
(Because of low solubility data are not available)
36 S Phenyl 208 ± 42 633 ± 108
37 SO Phenyl 94.6 ± 25.4 193 ± 59
38 SO2 Phenyl 160 ± 38 151 ± 27
Scheme 1. General synthetic method for the preparation of the title compounds
1–38. Reagents and conditions (i) base as NaOH or piperidine, temperature:
ambient temperature or 140 C.
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constraint settings were applied as to the Glide docking experi-
ments. The tolerance was set to 2 Å in both instances. The pose
prediction docking mode was used. Docking scores and MM/GBSA
calculation results of covalent complexes in kcal/mol are summar-
ised in Table 2.
Molecular dynamics simulations ranging between 1.2 and
175 ns were applied to a selected group of the compounds with-
out using constraints. All processes were initiated using Desmond
in Maestro. Output structures of a docking experiment with Type I
core constraints were used as starting points. SPC solvent model
was used and box boundaries were adjusted to a distance of 10Å
from the protein–ligand complexes in each axis. Net positive
charge of the protein was neutralised by chloride ions. 0.15M
NaCl was added to the systems in each instance. Simulations were
carried out using NPT conditions, at a constant temperature of
300 K and pressure of 1 atm, with Nose–Hoover chain thermostat
(1 ps relaxation time) and MTK barostat (2 ps relaxation time)
methods. The cut-off radius for coulombic interactions was set to
9 Å. The systems were relaxed before simulation using the default
relaxation process of Desmond57. The stability of (24) in the active
site was explored through a 175 ns simulation with 25 ps record-
ing intervals, and the Thermal MMGBSA script available in
Schr€odinger was used to obtain multiple binding free energy val-
ues for the complex, sampling every 100th frame of the
simulation. The 1.2 ns simulation of (24) was also conducted with
TIP3P water model to explore the nature of interactions on the ps
scale in a different MD setup.
Cell culture and treatments
In cell culture experiments, we used RAW264.7 mouse monocyte/
macrophage cell line (ECACC, Salisbury, UK; passage number:
8–15) and RAW-BlueTM cells (Invivogen, Toulouse France, passage
number: 10–14). RAW264.7 and RAW-BlueTM cells were cultured in
5% CO2 at 37 C in endotoxin-tested Dulbecco’s Modified Eagle’s
Medium (high glucose, 4.5g/L, 2mM L-glutamine; Corning, Corning
Incorporated Costar, Corning, NY) supplemented with 10% FBS. For
culturing RAW-BlueTM cells, we also added 100mg/ml normocin and
200mg/ml zeocin to the medium. The day before the experiments,
cells were plated onto 24- or 96-well plates and cultured overnight.
Then medium was replaced to fresh one and cells were induced by
0.1mg/ml or 1mg/ml lipopolysaccharide (LPS; E. coli, 0127:B8; Sigma-
Aldrich, Budapest, Hungary). The freshly synthesised tetralone deriva-
tives were dissolved in DMSO and applied in 20mM concentration as
a pre-treatment, added 30min before LPS induction. To exclude the
effects of vehicle, both CTRL and LPS-treated cells received the same
amount of DMSO.
Table 2. Glide XP docking scores and CovDock affinity scores of the compounds using type I and type II docking constraints.
Reversible Covalent
Type I Type II Type I Type II
docking score (XP)
MM/GBSA
dG Bind docking score (XP)
MM/GBSA
dG Bind cdock affinity
MM/GBSA
dG Bind cdock affinity
MM/GBSA
dG Bind
1 8.499 54.71 8.519 57.99 8.693 61.64 6.249 37.79
2 8.132 50.83 7.819 55.61 8.233 34.65 6.685 36.06
3 – – 6.134 28.08 7.312 24.51 6.981 36.11
4 8.213 52.36 7.034 42.78 8.188 35.80 6.140 47.58
5 8.210 53.75 4.216 46.44 8.141 37.61 5.607 24.69
6 8.135 52.37 7.225 38.32 8.269 45.84 6.819 27.79
7 8.309 55.48 8.360 51.57 8.045 50.49 7.748 6.62
8 8.193 51.5 6.560 39.76 8.046 36.68 6.685 43.60
9 8.052 53.51 5.437 36.13 8.183 37.85 6.176 34.18
10 8.204 50.87 6.788 53,12 8.626 41.35 6.855 34.79
11 8.236 57.97 7.176 20.02 7.897 42.24 7.804 46.15
12 7.926 52.70 6.785 44.62 8.186 40.35 6.525 48.47
13 8.278 57.06 7.075 42.91 8.024 52.93 7.111 32.16
14 8.209 51.36 – – 8.301 40.16 5.758 29.96
15 8.221 52.12 4.795 2.46 8.369 37.02 6.363 47.81
16 8.281 51.63 6.784 41.76 7.457 45.26 6.289 43.93
17 8.369 54.02 – – 8.464 45.79 5.367 44.99
18 8.143 50.91 6.521 41.23 8.197 46.33 6.542 41.71
19 7.935 53.14 7.953 57.54 7.890 41.16 6.452 44.63
20 8.063 54.70 7.505 54.38 8.308 34.01 6.735 32.73
21 8.019 51.92 7.732 54.85 8.000 28.22 7.221 34.68
22 7.929 54.38 6.722 49.94 7.823 39.63 6.360 18.93
23 8.200 50.17 6.152 36.16 8.344 39.62 6.480 35.48
24 8.227 55.40 7.714 60.28 8.504 42.35 7.072 33.41
25 8.093 50.90 6.606 53.61 8.256 41.14 7.077 35.23
26 8.206 50.79 6.501 54.63 8.601 40.48 6.242 32.12
27 8.425 56.44 6.836 56.88 8.533 48.12 6.750 34.59
28 8.289 58.79 7.046 44.12 8.837 48.69 6.608 33.40
29 8.196 58.01 6.252 43.46 8.228 49.88 7.206 28.65
30 8.315 58.44 4.182 47.12 8.667 50.57 5.632 36.95
31 8.132 54.03 4.606 41.29 8.560 51.83 6.300 34.00
32 8.500 61.06 6.732 15.06 8.626 45.56 6.887 9.84
33 8.341 57.21 6.865 48.23 7.404 50.21 6.634 39.94
34 8.195 54.00 8.28 43.08 8.134 44.49 7.360 27.69
35 – – – – – – – –
36 7.700 37.08 6.352 48.78 7.495 25.07 6.765 27.60
37 – – – – –5.623 –26.39 –6.764 –32.26
38 – – – – –5.975 12.70 – –
Calculated binding energies are provided for both, the reversible and covalent MIF-ligand complexes.
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ROS and nitrite production
To measure the amount of reactive oxygen species we seeded
RAW264.7 cells onto 96-well plates in a density of 105cells/well.
Cells were treated with the tetralones as a pre-treatment and they
were induced with 1 mg/ml LPS for 24 h. Then 2 mM dihydrorhod-
amine123 (DHR123; Life Technologies, Carlsbad, CA) fluorescent
dye was added and incubated for an additional 2 h. Fluorescent
intensity of the dye (excitation 490 nm/emission 510–570 nm) was
measured with Glomax Multi Detection System (PromegaVR ,
Madison, WI, USA).
For nitrite measurements, we applied the same culturing condi-
tions, treatments, and equipment as described above. After 24h of
incubation, 50ml medium was removed and added to equal amount
of Griess reagent (Sigma-Aldrich, St. Louis, MO, USA) in 96-well plate.
The optical density was measured at 550nm wavelength.
NF-jB activation
The detection of NF-jB activation was accomplished by using
RAW-BlueTM cells. RAW-BlueTM cells are genetically modified
RAW264.7 macrophages, which are able to secrete embryonic
alkaline phosphatase (EAP) upon LPS induction and following NF-
jB activation. The levels of EAP can be examined using QUANTI-
BlueTM detection medium.
RAW-BlueTM cells were seeded into 96-well plate at a density
of 105cells/well. Cells were treated with tetralones (pre-treatment,
20mM) and with 1 mg/ml LPS. 24 h after LPS treatment 20 ml
medium was removed and incubated with 100 ml QUANTI-BlueTM
detection medium (Invivogen; Toulouse, France) in 96-well plates.
The optical density was measured at 600 nm.
Cytokine production
For cytokine concentration measurements, RAW264.7 cells were
cultured in 24-well plates at a density of 5105 cells/well and
treated with tetralones (pre-treatment, 20mM) and with 1 mg/ml
LPS for 24 h. TNF-a, IL-6 and CCL-2 levels were determined from
the culturing media by using Ready-Set-Go ELISA kits (eBioscience,
San Diego, CA, USA) for TNF-a and IL-6 detection and mouse CCL-
2 uncoated ELISA-kit (Invitrogen, Vienna, Austria) for CCL-2 deter-
mination. ELISA-kits were applied as provided by the protocol of
the manufacturer, the optical density was measured at 450 nm.
Mouse thermometry studies
Thermophysiological experiments were performed in 24 C56BL/6
adult male mice. Experimental procedures were approved by the
Animal Research Review Committee of the University of Pecs,
Medical School (Permit number: BA02/2000–6/2018). At the time
of the experiments, the mice weighed 28± 4 g. Animals were
housed in temperature-controlled rooms on a 12/12 h light/dark
cycle. Standard rodent chow and tap water were available ad libi-
tum. All experimental procedures were carried out according to
the European Communities Council Directive of 2010/63/EU under
protocols approved by the Institutional Animal Use and Care
Committee of the University of Pecs. Mice were anaesthetised
with an intraperitoneal (i.p.) injection of ketamine-xylazine (81.7
and 9.3mg/kg, respectively) and received antibiotic prophylaxis
intramuscularly (gentamycin, 6mg/kg). During the surgery, mice
were kept on a heating pad (PECO Services Ltd., Brough, UK), and
then to prevent postsurgical hypothermia, the animals were
allowed to recover from anaesthesia in a temperature-controlled
chamber (model MIDI F230S; PL Maschine Ltd., Tarnok, Hungary)
set to 31 C. Each mouse was implanted intraperitoneally with a
miniature biotelemetry transmitter (G2 E-Mitter series; Starr Life
Sciences Corp., Oakmont, PA) to record abdominal temperature
(Tab) and general locomotor activity. The latter has been shown
to play an important thermoregulatory role in mice58–60. The
transmitter was inserted into the abdominal cavity through a
small midline incision and was fixed to the left side of the abdom-
inal wall with suture. The surgical wound was closed and the mice
were returned to their home cages. The mice were allowed a
2–3weeks post-surgical recovery period before an experiment.
Telemetry receivers (model ER-4000; Starr Life Sciences Corp.,
Oakmont, PA, USA) were positioned in a temperature-controlled
room, and the home cages of mice were placed on top of the
receivers, as described earlier59. The ambient temperature of the
room was set to 26 C, which is near the lower end of the thermo-
neutral zone for mice61. On the day of an experiment, compound
(24) at 1.6mg/kg or its vehicle (10% DMSO in saline) was adminis-
tered intraperitoneally in bolus (3.3ml/kg). Thirty minutes later,
either LPS (5.0mg/kg) from Escherichia coli 0111:B4 (Sigma-Aldrich,
St. Louis, MO) or saline was intraperitoneally injected to the mice.
Thermoregulatory responses were compared by two-way
ANOVA followed by Fisher LSD post hoc test, as appropriate, using
Sigma Plot version 11.0 (Systat Software, San Jose, CA, USA) with
the level of significance set at p< 0.05. The data are reported
as means ± SEM.
Results
Tautomerase assay
First the inhibitory effect on the ketonase reaction is discussed. As
regards the structure–activity relationship, the size of the cyclic
ketone ring has an impact on the inhibitory effect (see Table 1).
From the phenyl substituted compounds, the five-membered (1)
and the seven-membered (3) showed almost identical inhibitory
effect (IC50¼82.8 and 84.0mM, respectively), while the six-mem-
bered (2) exerted a lower activity (IC50¼127 mM). The substituted
derivatives of (2) containing both homoaromatic and hetero-
aromatic side chain were examined.
Summarising the results of the measurements studying the
possible inhibitors of ketonase reaction, the best inhibitors are the
compounds with a nonpolar aromatic side chain, such as the
methyl derivative (4), the ortho,para-dichloro compound (13) and
the polar 2-pyridyl derivative (24). Analysis of the structure–activ-
ity relationship is presented later on in more detail.
The inhibition of the enolase activity was also investigated. In
the group of the compounds with a homocyclic skeleton, some
good inhibitors can be found, such as five-membered phenyl
derivative (1) (IC50¼20.2 mM). Compounds with a heteroaryl side
chain produce the highest bioactivity. From the five-membered
derivatives the indolyl- (23, IC50¼2.89 mM), the furyl derivative (19,
IC50¼25.4mM) and the N-metylpyrrolyl compound (22,
IC50¼27.8mM) are the best inhibitors. As for the six-membered
ones, two pyridyl derivatives (24 and 25, IC50¼28.6 mM for both)
exerted the best activity, while the 4-pyridyl derivative (26) proved
to be a weaker enolase inhibitor. Comparing the enolase and
ketonase activity and focussing on the selectivity, some of our
compounds acted as good ketonase inhibitors having high select-
ivity, such as (4) (IC50enolase/IC50ketonase ¼ 13.9), (13)
(IC50enolase/IC50ketonase ¼18), (26) (IC50enolase/IC50ketonase
¼10), while the substance (23) (IC50ketonase/IC50enolase ¼20)
behaved as a strong and selective enolase inhibitor.
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Molecular modelling
Docking experiments
The majority of MIF inhibitors target the active site where enzym-
atic reactions take place. The protein is known to form homo-
trimers, in which binding sites are formed by each of two
adjacent chains. As represented in the Protein Data Bank entry
3IJJ, 4-hydroxyphenylpyruvate contacts with Pro1, Lys32 and Ile64
of monomer A, and Tyr95 and Asn97 of monomer C. Available
structures of MIF in complex with various inhibitors reveal the
importance of these residues in ligand binding62. Like the series
of compounds presented in this paper, many MIF inhibitors con-
tain more than one aromatic ring63, suggesting the extensive
involvement of p-interactions.
Reversible docking
Docking experiments revealed two possible types of binding
mode (Figure 2). In Type I complexes, the A and B rings occupy
the binding pocket. The ketone oxygen forms a hydrogen bond
with the peptide NH of Ile64A. The aromatic ring interacts with
Tyr95C through p–p stacking. The catalytic Pro1A and Lys32A are
in the proximity of the methylene bridge. The aryl or heteroaryl
group bonds with Lys32A, Tyr36A and Phe113A through hydro-
phobic and p-interactions. Such binding mode can be observed in
the PDB entry 3L5R of a 3-phenylchromen-4-one compound64. In
type II binding mode, where the ligand is horizontally flipped, the
C-ring interacts with Tyr95C, the ketone oxygen with Ile64A and
Lys32A, and the A ring with Tyr36A. A similar binding mode of a
structurally related covalent inhibitor can be observed in the PDB
entry 4Z1U65. After visual analysis and consideration of docking
scores, we propose Type I binding mode to be more favourable.
Covalent adduct formation
In the reversible docking models, the position of the electrophilic
methylene bridge relative to Pro1A hints at the possibility of a
covalent mechanism. Such catalytic proline residues reportedly
possess the ability to mediate enzymatic conversions through
covalent catalysis66. NAPQI has been shown to bind covalently to
Pro1, while exhibiting non-covalent inhibitory activity67. The cova-
lent mechanism of a series of MIF inhibitors has also been verified
by X-ray crystallography and enzymatic assays65, where both cova-
lent and non-covalent tautomerase inhibitory activity have been
attributed to “compound 12”, visible in PDB entry 4Z1U65.
Both Type I and Type II constraints were used for covalent
docking to assess whether any of the two determined binding
poses would be favourable for a covalent reaction to occur
between Pro1A and the methylene carbon. Covalent adduct for-
mation was successful for most molecules, with the exception of
(35) and (38) due to steric clashes. Covalent docking affinity and
MM/GBSA scores indicate that the reaction is more likely to hap-
pen in Type I binding mode (Table 2). Even though an increased
number of steric clashes with Asn97C, Tyr95C and Pro1A are vis-
ible, minimisation of the output structure results in a reasonable
covalent adduct (Figure 3).
Molecular dynamics
We conducted MD simulations to reveal binding characteristics
obscured by using a rigid protein structure for docking. The H-
bond between Ile64A and the ketone oxygen is a crucial contact.
The p–p stacking between the A ring and Tyr95C is a T-type stack-
ing interaction. Weak hydrophobic contacts with Val106A and
Met2A are present. The arylmethylene substituent is exposed to
Figure 2. Type I (left) and Type II (right) binding modes of tetralones in the active site of MIF, identified through reversible docking experiments. Carbons of (24) are
coloured orange (Type I) and yellow (Type II). Residues are coloured according to their type of interaction with the ligand: yellow residues form H-bonds, blue residues
form p–p stacking and green form cation-p interactions, red residues are hydrophobic, and the catalytic Pro1 is coloured cyan. The grey area is the inner surface of
the binding site. Red dashed lines indicate steric clashes.
Figure 3. Compound 24 covalently bound to Pro1A of MIF in Type I binding
mode. The H-bond with Ile64A is represented by the yellow, and the p–p stacking
with Tyr95C by the blue dashed line. The docking output structure was minimised
to avoid clashes due to the rigid receptor model. Active site residues involved in
reversible binding are shown. Some atoms are hidden for clearer view of the
covalent adduct.
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the solvent (see ligand RMSF in Supplementary material, Figure
S2) and forms a sandwich-type p–p stacking with Tyr36A. Rotation
of the C-ring is hindered by constant interactions with Lys32A,
Tyr36A and Phe113A (Supplementary material, Figure S3). A steric
clash may occur for 3-substituted phenylmethylene-tetralones
such as the inactive analogue (9). The protonated amino group of
Lys32A is capable of forming a cation-p bond with the C-ring,
especially of heteroaryl derivatives (22–26). The interaction is less
pronounced for phenyl compounds, such as (4) and (13), and vir-
tually absent from models of (9). All three interactions can be pre-
sent concurrently. A water molecule can also be involved in
ligand binding, where the catalytic Pro1A and the adjacent Tyr36A
interacts with the ligand through a water bridge. The hydrogen of
the water molecule occasionally engages in close contact with the
methylene carbon or interacts with heteroatoms and halogen sub-
stituents of the C ring.
The importance of the interaction is most pronounced in the
case of (24), where the 2-pyridyl nitrogen is adequately positioned
to maintain a constant water bridge interaction (Figure 4).
Consequently, a stable complex forms between (24) and MIF,
where no major conformational change is observed for 65 ns. The
presence of interactions in percentage of frames are: Ile64A(H-bond)
¼ 65%; Tyr95C(p–p) ¼ 64%, Lys32A(cation–p) ¼ 69%, Pro1A(water
bridge) ¼ 91%, Tyr36A(water bridge) ¼ 83%. Additionally, p–p interac-
tions with Tyr36A and Phe113A were observed in 18% of the
frames for both residues. The most prominent weak hydrophobic
contacts are formed with Met2A, Tyr36A, Val106A and Phe113A
and are present throughout the entirety of the simulation. The
averaged free binding energy was calculated at 59.32 kcal/mol
(max¼51.19, min¼68.75; SD ¼ 3.40) for this phase. Minor pro-
tein and ligand movements at 65 ns result in (24) assuming a min-
imally altered, but stable position until 138.79 ns. In this phase of
roughly 73 ns in length, H-bond interaction with Ile64A diminish
to 21% as it forms weak hydrophobic contacts instead, and p–p
interaction with Tyr95C falls to 2%. The water bridge interaction
becomes even more pronounced with 94% and 90% presence
rates for Pro1A and Tyr36A. Lys32A and Phe113A continue to
interact with the p –electron system of the C ring (60% and 32%).
Free binding energies for this phase were calculated at an average
of 54.82 kcal/mol (max¼46.95, min=-63.18; SD ¼ 3.88). At
138.79 ns Trp108A disrupts binding as it intrudes the active site,
which results in cessation of most H-bond and p interactions, and
the distancing of the methylene carbon from Pro1A as well. As a
result, (24) undergoes a major positional shift, and only p–p stack-
ing interactions of the C-ring with Phe113A and Trp108A are vis-
ible with 41% and 27% frequencies. Weak hydrophobic contacts
with Phe49C and Tyr95C also develop. The complex remains
unchanged until the end point of the 175 ns simulation (see
Supplementary material Figures S4–S7 for RMSD plot and active
site residue contributions).
In simulation of (24) using TIP3P water model, the phenolic
oxygen of Tyr95C acts as the H-acceptor instead of Tyr36A; such
model describing an enolate intermediate was published previ-
ously68. We have also identified a potential chloride ion binding
motif at the active site. Chloride binding in MIF may be a remnant
of a lost dehalogenase function. Such enzymatic activity is exhib-
ited by structurally related bacterial tautomerases CaaD and cis-
CaaD, of which the former also possesses a phenylpyruvate tauto-
merase activity similar to that of MIF6.
Structure–activity relationship
Both aromatic rings interact with active site residues. The ideal size
for the B ring is either 5 or 6 atoms without any substituents; larger
ring systems are less favourable. The 1-tetralone ring is preferred
over 4-chromanones, and thiochromanone analogues have even
weaker effect. The ortho-substitution of the C ring, as well as
switching an ortho-carbon to nitrogen, is favourable for a water
bridge interaction with Pro1A to occur. The heterocyclic nitrogen of
(24) and, to a lesser extent, the 2-chloro substituent of (13), are
able to bind a water molecule. For the 3-pyridyl and 4-pyridyl ana-
logues (25) and (26), or the 3-bromo substituted (9), no persistent
water bridge interaction is observed. Certain para-substituents are
partially solvated, or can interact with the phenolic hydroxyl of
Tyr36A. Some may also stabilise the molecule and prevent changes
in binding pose. Meta-substituents seem to prevent tighter binding,
possibly due to steric clashes with proximal residues. Changing in
the phenyl group meta- or para-carbon to nitrogen, also enhances
inhibitory activity, although to a lesser extent compared to the 2-
pyridyl analogue. Changing the phenyl ring to a 5-membered het-
erocycle mostly increases activity, although not for unsubstituted
pyrrolyl derivative (21), that shows somewhat weaker effect com-
pared to the phenyl analogue. Electron rich derivatives such as (23)
are more likely to interact with the active site lysines, while elec-
tron-deficient rings are less likely to do so.
Macrophage activation
Tetralone derivatives reduce ROS and NO production in LPS-
induced macrophages
MIF has been involved for long in the pathomechanism of inflam-
mation including macrophage activation. One of the most import-
ant signs of inflammatory macrophage induction is the production
of reactive oxygen and nitrogen species, like superoxide (O2
) and
nitrogen monoxide (NO)69. Therefore, we measured ROS and nitrite
(NO rapidly oxidises to NO2
 in the medium of cells) production of
LPS-induced and tetralone derivatives-treated RAW264.7 macro-
phage cells. 24h after LPS treatment we detected a significant,
approximately 3-fold increase in ROS production compared to the
basal level of vehicle-treated control cells (Figure 5(A)). Three out of
the five selected compounds slightly inhibited ROS production. To
Figure 4. Interactions between the active site residues and compound 24 as it
maintains its binding conformation. Both an active site-bound water molecule
and a chloride ion are visible. Hydrogen bonds are represented by yellow, p–p
stackings by blue, cation-p interactions by green and ionic bonds by purple
dashed lines. The grey area represents the inner surface of the binding site.
Some atoms of active site residues are not shown for clearer view on
interactions.
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be more precise, we detected at about 20% decrease in ROS con-
centrations of (24)-, (26)- and (32)-treated, LPS-activated cells. In
contrast to these (4) failed to modify ROS level and surprisingly,
(23) induced a slight increase in it. Nitrite concentrations were
found to be considerably increased (20-fold) by LPS treatment
(Figure 5(B)), however in the media of (24)-, (26)- and (32)-treated
active macrophages, we detected markedly lower nitrite concentra-
tions (50%). Interestingly, compounds (4) and (23) could also
inhibit nitrite production, but to a lower extent.
Majority of tetralone derivatives diminish NF-jB activation in
macrophages
NF-jB is an inflammatory transcription factor, which can be acti-
vated by PAMPs, like LPS via TLR470 or even by oxidative stress71
and induces proinflammatory protein expression. LPS induced a
dramatic increase (40-fold) in the transcriptional activity of NF-
jB compared to DMSO-control (Figure 6). We found slight, but
statistically significant inhibitory effect in the case of (24), (26),
(23) and (4) treatments, in relation to the LPS-activated cells.
Compound (32) could not show any reducing effect on NF-
jB activation.
Tetralone derivatives modulate cytokine and chemokine produc-
tion in RAW264.7 cells
NF-jB participates in the protein expression of many inflammatory
cytokines, like TNF-a, IL-672 and chemokines like, CCL273. Levels of
TNF-a, IL-6 and CCL2 were measured in the media of activated
macrophages upon tetralone treatments. LPS induced a powerful
increase (5–20-fold) in the concentrations of all investigated
cytokines and chemokines (Figure 7). (24), (26) and (32) reduced
TNF-a production, but (23) and (32) failed to do so (Figure 7(A)).
In case of IL-6 all of the five selected tetralone compounds could
diminish IL-6 production, but (24), (26) and (32) had the most
dominant effect (Figure 7(B)). CCL2 levels were also negatively
modified by all of the investigated tetralones, which showed com-
parable inhibitory efficacy (Figure 7(C)).
Thermophysiology
The administration of compound (24) or its vehicle on its own did
not cause any change in the abdominal temperature (Tab) and
locomotor activity of the mice. On the contrary, the applied high
dose (5.0mg/kg i.p.) of LPS in a near subthermoneutral environ-
ment caused marked hypothermia and hypokinesis in vehicle-pre-
treated mice (Figure 8), as expected74. Compared to saline, LPS
caused a significant drop in Tab of vehicle-pre-treated mice from
8 to 22 h post-administration (p< 0.05), with the biggest inter-
group difference of 2.3 C at 13–14 h (p< 0.001). The LPS-induced
hypothermia was brought about, at least in part, by suppressed
locomotor activity, which was lower in LPS-treated than in saline-
treated mice throughout the experiment and was significantly dif-
ferent between the groups at 11 h (p< 0.05) and from 13 to 22 h
post-administration (p< 0.001) (Figure 8). Pre-treatment of the
mice with compound (24) exaggerated and prolonged the LPS-
induced decrease in Tab. In compound (24)-pre-treated mice the
LPS hypothermia was significant from 7 to 24 h post-administra-
tion, compared to saline-treated mice, with the biggest intergroup
difference of 4.1 C at 14 h post-administration (p< 0.001).
Importantly, the decrease of Tab in response to LPS was signifi-
cantly more pronounced in mice pre-treated with compound (24)
than in vehicle-pre-treated mice between 10 and 24 h post-LPS
administration (p< 0.05). The LPS-induced decrease in locomotor
activity could be also observed throughout the experiment after
pre-treatment with compound (24), and did not differ from what
was seen in vehicle-pre-treated mice. However, it should be noted
that the locomotor activity was reduced to near-zero level in both
LPS-treated groups, thus an exaggeration of the response (i.e. a
further decrease) to compound (24) was hardly possible.
Figure 5. Tetralone derivatives reduce ROS and nitrite production. RAW264.7 cells
were pre-treated with tetralones for 30min and they were induced by 1lg/ml
LPS for 24 h. (A) ROS production was measured by using 2lM dihydrorhodamine
123 fluorescent dye (fluorescent intensity was measured at 490 nm [excitation]/
510–570 nm [emission] wavelengths). (B) Nitrite production was evaluated by
applying Griess reagent (optical density was measured at 550 nm). Data are pre-
sented as means± SD in percentage of LPS-treated group; n¼ 3 6 (pooled data
of 3 independent experiments with 6 parallels); Student’s t test, p values < 0.05
were considered significant.  p< 0.05;  p< 0.01;  p< 0.001; n.s. ¼ non-
significant.
Figure 6. The effect of tetralone derivatives on NF-jB production. NF-jB activa-
tion in macrophages was evaluated by using RAW-BlueTM cells. Macrophages
were pre-treated with tetralones for 30min and they were induced by 1lg/ml
LPS for 24 h. The activity of secreted embryonic alkaline phosphatase was meas-
ured by using QUANTI-BlueTM detection medium. The optical density was meas-
ured at 600 nm. Data are presented as means± SD in percentage of LPS-treated
group; n¼ 3 6 (pooled data of three independent experiments with six paral-
lels); Student’s t test, p values <0.05 were considered significant. p< 0.001;
n.s.¼non-significant.
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Discussion
As regards the mechanism of action of the test compounds, we
suppose, similarly to other authors, the importance of the N-ter-
minal proline. The role of this basic amino acid in the mechanism
of MIF was discussed by some researchers75. Mc Lean et al.
studied hydroxyquinoline derivatives as efficient MIF inhibitors76.
Applying crystallographic methods they were able to detect the
covalent adduct formed in the reaction of Pro1 and an intermedi-
ate unsaturated ketone (“quinone methide”). Similar observations
were made by Orita et al. also using hydroxyquinolines25.
Our test compounds, the cyclic a,b-unsaturated ketones are
well known alkylators reacting with nucleophiles (amines, thiols)
in the b-position in a Michael addition. They show a preferential
affinity towards the thiols77. Thus, we suggest a Michael addition
with Pro1 for our test compounds. This type of synthetic product
has been described by Shankar et al. when reacting enones with
piperidine78. The corroboration of the proposed mechanism is
under progress.
Concerning potential anti-inflammatory activity of the tetralone
analogues reported here, it is noteworthy that certain herbs used
against inflammatory conditions are rich in tetralone
substances79,80.
Next, we intended to give a picture of the biological efficacy of
five preferred tetralone derivatives, namely (4), (23), (24), (26) and
(32). These compounds were selected based on their excellent
tautomerase inhibitor activity, i.e. they are potent MIF inhibitors
(see Table 1). The most efficient compounds, namely (24):
(IC50¼5.63mM for ketonase activity) or (32): (IC50¼4.31 mM for
ketonase activity) are even more powerful pharmacological inhibi-
tors, than the well-known and widely accepted ISO-1 (14.41mM)23.
Since a strong association between tautomerase inhibition and
attenuation of inflammatory macrophage activation exists81, and
other MIF inhibitors were previously found to possess anti-inflam-
matory effects in LPS-induced RAW264.7 macrophages82, we
decided to use this model in our investigations as well.
All of the chosen tetralone derivatives were found to have
anti-inflammatory potencies in activated macrophages, but two of
them (24 and 26) showed remarkably powerful effects. These two
compounds inhibited ROS and NO production, NF-jB activation,
Figure 8. The effect of compound 24 on thermoregulation and locomotor activ-
ity in mice. The effects of compound 24 (or vehicle) pre-treatment at 30min
on the abdominal temperature (top) and locomotor activity (bottom) of mice
treated with lipopolysaccharide (LPS) or saline at time zero (doses indicated). Pre-
treatment with compound 24 significantly exaggerates the hypothermic response
to LPS, while it does not further reduce the already near-zero level of locomotor
activity in LPS-treated mice. The number of mice was 8 (n¼ 8) in each group.
Data are presented as means± SD.
Figure 7. Cytokine production of activated macrophages: (A) TNF-a; (B) IL-6; (C)
CCL-2. LPS-activated RAW264.7 cells were pre-treated with tetralones for 30min
and they were induced by 1lg/ml LPS for 24 h. Cytokine concentrations were
measured with ELISA-kits, optical density was measured at 450 nm. Data are pre-
sented as means± SD in percentage of LPS-treated group; n¼ 6; Student’s t test;
p values < 0.05 were considered significant. p< 0.01; p< 0.001; n.s. ¼
non-significant.
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and expression of the investigated cytokines (TNF-a, IL-6, CCL-2). It
is important to note, that these molecules have similar structures;
they are isomeric compounds where only the position of the
nitrogen atom differs. Compound (4), however, with a quite simi-
lar methyl substituted structure was found to have only moderate
effects compared to (24) and (26). The third best compound (32)
had very similar effects on RONS and cytokine production, like
(24) and (26), but surprisingly it could not inhibit NF-jB activation.
Compound (32) is a methoxy substituted compound without
nitrogen in the six membered C-ring and it has oxygen in its chro-
manone ring system compared to (24) and (26). Compound (23),
the least effective tetralone in the investigated group also lacks a
pyridyl ring, since it is an indolyl-compound. These findings might
underline the importance of the pyridyl moiety in the biological
activity of the investigated MIF inhibitors.
In thermophysiological experiments, we studied the effect of
compound (24), a potent, preferential ketonase inhibitor (Table 1),
on LPS-induced hypothermia in freely moving mice. This experi-
mental model resembles the manifestation of severe forms of sys-
temic inflammation (e.g. septic shock)74. We found that pre-
treatment of the mice with compound (24) augmented the hypo-
thermic response to high-dose LPS in mice, suggesting that the
enzymatic, mostly ketonase, activity of MIF plays a limiting role in
the thermoregulatory changes associated with severe forms of sys-
temic inflammation.
Circulating inflammatory cytokines are known to be involved in
the mediation of endotoxin-induced fever and hypothermia74,81,83,
but the key cryogenic substances responsible for triggering the
hypothermic response in severe systemic inflammation are still
not entirely identified. LPS binds to toll-like receptor 4, which
results in the activation of the NF-jB, thereby leading to the
expression of proinflammatory cytokines such as tumour necrosis
factor (TNF)-a, interleukin (IL)-1ß, and IL-6. At moderate-to-high
concentrations TNF-a causes hypothermia, and, at present, it is
considered to be the most important cryogenic mediator, whereas
IL-6 is the most important pyrogenic cytokine74. MIF, as a potent
proinflammatory cytokine, also plays an important role in systemic
inflammation84, however, to our knowledge; it has not been clari-
fied whether it also contributes to the thermoregulatory manifes-
tations of the disease. In the present study, we demonstrated, for
the first time, that LPS hypothermia is more pronounced when
the ketonase (and possibly, to lesser extent, the enolase) activity
of MIF is inhibited. These findings suggest that the enzymatic
activity of MIF limits the effects of the endogenous, thermally
active mediators, e.g. IL-6 and TNF-a, in severe systemic inflamma-
tion. In accordance, MIF tautomerase inhibitors blocked the pro-
duction of TNF-a and to a bigger extent that of IL-6 in infected
mice in vivo85, as well as, in LPS-activated macrophages in vitro in
the present study (Figure 7). Compound (24) inhibits the ketonase
activity of MIF with a five-fold higher potency than its enolase
activity, but it cannot be ruled out that the enolase activity was
also inhibited by the applied dose of compound (24) to some
extent, therefore, that the enolase activity of MIF also plays a role
in the control of the systemic inflammation-associated hypother-
mic response. The contribution of MIF and its enzymatic activities
to the thermoregulatory manifestation of mild and moderate
forms of systemic inflammation, which are typically accompanied
by fever, also remain subject of future studies.
In conclusion, we have selected two families of compounds, E-
2-arylmethylene-1-tetralones and their heteroanalogues as poten-
tial MIF inhibitors. The type and the size of the B-ring and the
substitution pattern of the C-ring have a high impact on the bio-
activity. From the compounds with unsubstituted C-ring the best
inhibitor of the ketonase was the five membered indanone deriva-
tive (1). As regards the tetralone derivatives with homoaromatic
rings the p-methyl derivative (4) showed the highest activity. As
for the heteroaromatic C-rings, the five-membered derivatives as
the indolyl- (23), the furyl derivative (9) and N-metylpyrrolyl com-
pound (22) proved to be the most efficient. From the derivatives
with six membered heteroaromatic C-ring, the 2-pyridyl substance
(24) was the most efficient. The inhibitory effect of the enolase
was much weaker. Some test substances, such as (4), p-methyl
derivative possessed high selectivity. The possible mechanism of
action is probably based on a Michael addition between the
enone groups of the test compounds and the Pro1 of MIF. The
selected five compounds (4), (23), (24), (26) and (32) inhibited
LPS-induced macrophage activation, but to different extent. The
pyridyl-derivatives (24) and (26) showed the highest potency,
which might underline the importance of six membered hetero-
aromatic C-ring in the biological efficacy of our MIF inhibitors. We
have determined a binding model for the compounds through
docking experiments, and generated a custom covalent docking
protocol, which we used to provide the structure of the hypothes-
ised covalent adduct with Pro1. Through MD simulations, we have
demonstrated that the determined reversible binding mode is sta-
ble, and covalent reaction between Pro1 and the electrophilic
methylene carbon may be possible. Our work provide useful infor-
mation for further understanding the ligand binding of MIF, and
could be of aid in designing more potent inhibitors.
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